SG11201706104XA - CRYSTALLINE FORM OF S-(4-(3-FLUORO-3-METHYLBUTYRYLOXY)BUT-2-YNYL)6a,9a-DIFLUORO-17a,-(FURAN-2-YL)CARBONYLOXY-11ß-HYDROXY-16a-METHY1-3-OXOANDROSTA-1,4-DIENE-17ß-CARBOTHIOATE - Google Patents

CRYSTALLINE FORM OF S-(4-(3-FLUORO-3-METHYLBUTYRYLOXY)BUT-2-YNYL)6a,9a-DIFLUORO-17a,-(FURAN-2-YL)CARBONYLOXY-11ß-HYDROXY-16a-METHY1-3-OXOANDROSTA-1,4-DIENE-17ß-CARBOTHIOATE

Info

Publication number
SG11201706104XA
SG11201706104XA SG11201706104XA SG11201706104XA SG11201706104XA SG 11201706104X A SG11201706104X A SG 11201706104XA SG 11201706104X A SG11201706104X A SG 11201706104XA SG 11201706104X A SG11201706104X A SG 11201706104XA SG 11201706104X A SG11201706104X A SG 11201706104XA
Authority
SG
Singapore
Prior art keywords
oxoandrosta
methylbutyryloxy
carbothioate
methy1
ynyl
Prior art date
Application number
SG11201706104XA
Inventor
Jiten Ranchhodbhai Patel
Gopalkumar Chimanlal Patel
Gaurav Sanjivkumar Sheth
Trinadha Rao Chitturi
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of SG11201706104XA publication Critical patent/SG11201706104XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
SG11201706104XA 2015-01-31 2016-01-30 CRYSTALLINE FORM OF S-(4-(3-FLUORO-3-METHYLBUTYRYLOXY)BUT-2-YNYL)6a,9a-DIFLUORO-17a,-(FURAN-2-YL)CARBONYLOXY-11ß-HYDROXY-16a-METHY1-3-OXOANDROSTA-1,4-DIENE-17ß-CARBOTHIOATE SG11201706104XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN323MU2015 2015-01-31
PCT/IN2016/050034 WO2016120894A1 (en) 2015-01-31 2016-01-30 CRYSTALLINE FORM OF S-(4-(3-FLUORO-3-METHYLBUTYRYLOXY)BUT-2-YNYL)6α,9α-DIFLUORO-17α,-(FURAN-2-YL)CARBONYLOXY-11β-HYDROXY-16α-METHY1-3-OXOANDROSTA-1,4-DIENE-17β-CARBOTHIOATE

Publications (1)

Publication Number Publication Date
SG11201706104XA true SG11201706104XA (en) 2017-08-30

Family

ID=56542571

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201706104XA SG11201706104XA (en) 2015-01-31 2016-01-30 CRYSTALLINE FORM OF S-(4-(3-FLUORO-3-METHYLBUTYRYLOXY)BUT-2-YNYL)6a,9a-DIFLUORO-17a,-(FURAN-2-YL)CARBONYLOXY-11ß-HYDROXY-16a-METHY1-3-OXOANDROSTA-1,4-DIENE-17ß-CARBOTHIOATE

Country Status (14)

Country Link
US (1) US10179800B2 (en)
EP (1) EP3250582A4 (en)
JP (1) JP2018503667A (en)
KR (1) KR20170106377A (en)
CN (1) CN107428796A (en)
AU (1) AU2016210812A1 (en)
BR (1) BR112017016230A2 (en)
CA (1) CA2975363A1 (en)
EA (1) EA201791741A1 (en)
IL (1) IL253717A0 (en)
MX (1) MX2017009918A (en)
PH (1) PH12017501360A1 (en)
SG (1) SG11201706104XA (en)
WO (1) WO2016120894A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179800B2 (en) 2015-01-31 2019-01-15 Sun Pharma Advanced Research Company Limited Crystalline forms of S-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl] 6-α,9-α-difluoro-17-α-(furan-2-yl)carbonyloxy-11-β-hydroxy-16-α-methyl-3-oxoandrosta-1,4-diene-17-β-carbothioate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2912400A1 (en) * 2013-05-28 2014-12-04 Sun Pharma Advanced Research Company Limited Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl]6.alpha.,9.alpha.-difluoro-17.alpha.-(furan-2-yl)carbonyloxy-11.beta.-hydroxy-16.alpha.-methyl-3-oxoandrosta-1,4-diene-17.beta.-carbothioate
US10179800B2 (en) 2015-01-31 2019-01-15 Sun Pharma Advanced Research Company Limited Crystalline forms of S-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl] 6-α,9-α-difluoro-17-α-(furan-2-yl)carbonyloxy-11-β-hydroxy-16-α-methyl-3-oxoandrosta-1,4-diene-17-β-carbothioate

Also Published As

Publication number Publication date
WO2016120894A1 (en) 2016-08-04
KR20170106377A (en) 2017-09-20
EA201791741A1 (en) 2017-12-29
US20180016297A1 (en) 2018-01-18
EP3250582A4 (en) 2018-09-26
PH12017501360A1 (en) 2017-12-11
US10179800B2 (en) 2019-01-15
BR112017016230A2 (en) 2018-03-27
CA2975363A1 (en) 2016-08-04
IL253717A0 (en) 2017-09-28
MX2017009918A (en) 2018-11-09
CN107428796A (en) 2017-12-01
EP3250582A1 (en) 2017-12-06
JP2018503667A (en) 2018-02-08
AU2016210812A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
HK1247726A1 (en) Crystalline form of nicotinamide riboside
IL246474A0 (en) Heteroaryl substituted nicotinamide compounds
HK1252845A1 (en) Crystalline form of lorlatinib free base
PL3174891T3 (en) Crystalline form of nicotinamide riboside
HK1248070A1 (en) Heterocyclic compounds as kinase inhbitors
HK1246667A1 (en) 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as jak inhibitors
HK1255112A1 (en) Crystalline form of gemcitabine
HK1258964A1 (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
HK1231479A1 (en) Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-n,2- dimethylbenzofuran-3-carboxamide 6-((67--4-))-n2--3-
ZA201701132B (en) Novel 2,5-substituted pyrimidines as pde inhibitors
ZA201608442B (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
HK1256825A1 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
IL270961A (en) Crystalline form of n-butyldeoxygalactonojirimycin
PL3515454T3 (en) Crystalline polymorphic form of 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-oxo-2lambda5-[1,2]oxaphosphinane
IL248918A0 (en) Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile
IL253717A0 (en) Crystalline form of s-(4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl)6a,9a-difluoro-17a,-(furan-2-yl)carbonyloxy-11b-hydroxy-16a-methy1-3-oxoandrosta-1,4-diene-17b-carbothioate
GB201600977D0 (en) Novel crystalline form of picoxystrobin, method of preparing use of the same
HK1255122A1 (en) Novel composition for improved sleep